Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm pembrolizumab study in recurrent treatment-resistant atypical or anaplastic meningioma
MOH_2017-11-13_001891Phase 2Not yet recruiting
- Sponsor
- ד"ר שלומית יוסט-כ"ץ
- Start
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in meningioma, sponsored by ד"ר שלומית יוסט-כ"ץ. Primary endpoints: Safety and tolerability, Quality of life and 3 more. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
03
Conditions
meningioma
Beyond the preview
Go deeper on MOH_2017-11-13_001891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-13_001891.